BioStem Technologies (OTCMKTS:BSEM - Get Free Report) will likely be announcing its earnings results after the market closes on Monday, April 7th. Analysts expect the company to announce earnings of $0.37 per share and revenue of $86.69 million for the quarter.
BioStem Technologies Stock Up 3.7 %
Shares of BioStem Technologies stock traded up $0.30 during trading hours on Thursday, hitting $8.50. 41,394 shares of the company's stock traded hands, compared to its average volume of 59,850. BioStem Technologies has a twelve month low of $6.77 and a twelve month high of $28.26. The stock has a 50 day simple moving average of $12.86 and a 200-day simple moving average of $13.77. The company has a market cap of $141.98 million, a PE ratio of 12.50 and a beta of -0.39.
About BioStem Technologies
(
Get Free Report)
BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
Read More
Before you consider BioStem Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioStem Technologies wasn't on the list.
While BioStem Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
